What a GLP-1 Actually Does to Your Blood Sugar — the Part Your A1C Can't Show

Your A1C is an average. It tells you roughly where your blood sugar has lived for three months, and it tells you almost nothing about the ride: the climb after breakfast, the dip before lunch, the hours spent too high. Two people can share the same A1C and have completely different days. A continuous glucose monitor (CGM) shows the ride, and a GLP-1 changes it.

So what does a GLP-1 receptor agonist actually do to the number on your sensor? Whether you take semaglutide (Ozempic, Wegovy), liraglutide, or dulaglutide, the answer starts after you eat.

GLP-1s work on the spikes, not just the average

Three things happen at once, and all three land on the glucose surge that follows a meal. The drug restores glucose-dependent insulin release, so your body puts out more insulin exactly when blood sugar is rising. It suppresses glucagon, the hormone that pushes glucose up. And it slows how fast your stomach empties, so the meal reaches your bloodstream as a gentle rise instead of a cliff (Thomas 2023). The result is a flatter post-meal curve, which happens to be the single biggest driver of glucose variability and the thing a CGM makes impossible to miss.

It's the biggest variability reducer of any diabetes drug class

This part is well measured. When researchers ranked the major glucose-lowering drug classes against each other for their effect on glucose swings, GLP-1 receptor agonists finished first. In people with type 2 diabetes, they cut the mean amplitude of glucose excursions (MAGE) by about 25 mg/dL versus placebo and ranked ahead of every other class (Oh 2022). DPP-4 inhibitors came second. The older insulin secretagogues were well back.

One detail matters more than the ranking: this flattening is largely separate from how much the drug lowers your average glucose. It's a second, distinct benefit, and it's the one your lab report was never built to show.

Why your A1C hides all of this

A1C is a weighted average over roughly 90 days. Average is a real, useful number, but it erases the shape of the day. You can post a respectable A1C while spiking to 200 after every meal and dipping in between, because the highs and lows cancel out on paper. CGM metrics like time in range and coefficient of variation exist precisely because average glucose leaves this out (Chehregosha 2019). That gap is also why a GLP-1's effect often looks bigger on your sensor than in your bloodwork. The drug is working on exactly what the lab test averages away.

What this means if you're not diabetic

The mechanism above is ordinary gut and pancreas biology. It does not switch off in people without diabetes. But the numbers in this piece come from type 2 diabetes trials, and there are essentially no controlled variability studies in people without diabetes yet. So if you're on a GLP-1 for weight and watching a CGM, hold the honest version: expect to see your own response on the sensor, not a guaranteed figure borrowed from a diabetes trial. Watch your own curve. That's what the sensor is for.

Bottom line, a GLP-1 flattens the peaks a CGM was built to show and an A1C was never designed to catch. If you want to know what your drug is doing to your blood sugar day to day, the sensor is the instrument, and after meals is where you'll see it first.